Long-term outcome of pleurodesis with OK-432 in metastatic breast cancer: A new risk model for success from an analysis of 75 cases

International Journal of Clinical Oncology

Volumn 17, Issue 5, 2012, Pages 470-476

  Matsubara, Nobuaki ^a   Itoh, Kuniaki ^a   Mukai, Hirofumi ^a   Nagai, Shunji ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Breast cancer; Malignant pleural effusion; OK 432; Pleurodesis; Prognostic factors; Risk factors

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; NONSTEROID ANTIINFLAMMATORY AGENT; PICIBANIL; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CHEMICAL PLEURODESIS; DISEASE CONTROL; DRUG FEVER; DRUG USE; EXTUBATION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALIGNANT PLEURA EFFUSION; MEDICAL PROCEDURES; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK FACTOR; SURGICAL DRAINAGE; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PICIBANIL; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84869490812     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0312-5     Document Type: Article

References (32)

1. Marel M, Zrustova M, Stasny B et al (1993) The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest 104:1486-1489
2. Figlin R, Mendoza E, Piantadosi S et al (1994) Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861. Chest 106(6 Suppl):363S-366S
3. American Thoracic Society (2000) Management of malignant pleural effusions. Am J Respir Crit Care Med 162:1987-2001
4. Martinez-Moragon E, Aparicio J, Sanchis J et al (1998) Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 65:108-113
5. Lynch TJ Jr (1993) Management of malignant pleural effusions. Chest 103(4 Suppl):385S-389S
6. Barbetakis N, Asteriou C, Papadopoulou F et al (2010) Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases. J Cardiothorac Surg 5:27
7. Sahn SA (1997) Pleural diseases related to metastatic malignancies. Eur Respir J 10:1907-1913
8. Uzbeck MH, Almeida FA, Sarkiss MG et al (2010) Management of malignant pleural effusions. Adv Ther 27:334-347
9. Antunes G, Neville E, Duffy J et al (2003) BTS guidelines for the management of malignant pleural effusions. Thorax 58(Suppl 2): ii29-ii38
10. Tan C, Sedrakyan A, Browne J et al (2006) The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 29:829-838
11. Aydogmus U, Ozdemir S, Cansever L et al (2009) Bedside talc pleurodesis for malignant pleural effusion: factors affecting success. Ann Surg Oncol 16:745-750
12. Dresler CM, Olak J, Herndon JE 2nd et al (2005) Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 127:909-915
13. Okamoto H, Shoin S, Koshimura S et al (1967) Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 1:323-326
14. Antony VB, Loddenkemper R, Astoul P et al (2001) Management of malignant pleural effusions. Eur Respir J 18:402-419
15. Maskell NA, Butland RJ (2003) BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 58(Suppl 2):ii8-ii17
16. Villena Garrido V, Ferrer Sancho J, Hernandez Blasco L et al (2006) Diagnosis and treatment of pleural effusion. Arch Bronconeumol 42:349-372
17. Cohen RG, Shely WW, Thompson SE et al (1996) Talc pleurodesis: talc slurry versus thoracoscopic talc insufflation in a porcine model. Ann Thorac Surg 62:1000-1002 (discussion 1003-1004)
18. de Campos JR, Vargas FS, de Campos Werebe E et al (2001) Thoracoscopy talc poudrage: a 15-year experience. Chest 119:801-806
19. Stefani A, Natali P, Casali C et al (2006) Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study. Eur J Cardiothorac Surg 30:827-832
20. Good JT Jr, Taryle DA, Sahn SA (1985) The pathogenesis of low glucose, low pH malignant effusions. Am Rev Respir Dis 131:737-741
21. Rodriguez-Panadero F, Lopez Mejias J (1989) Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 139:663-667
22. Rodriguez-Panadero F, Lopez-Mejias J (1989) Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies. Chest 95:320-324
23. Light RW, Ball WC Jr (1973) Lactate dehydrogenase isoenzymes in pleural effusions. Am Rev Respir Dis 108:660-664
24. Hinz B, Cheremina O, Brune K (2008) Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 22:383-390
25. Botting RM (2000) Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis 31(Suppl 5):S202- S210
26. Sanchez-Armengol A, Rodriguez-Panadero F (1993) Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases. Chest 104(5):1482-1485
27. Largillier R, Ferrero JM, Doyen J et al (2008) Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 19:2012-2019
28. Maki DD, Grossman RI (2000) Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol 21:1064-1066
29. Davidson B, Konstantinovsky S, Nielsen S et al (2004) Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res 10:7335-7346
30. Reshad K, Inui K, Takeuchi Y et al (1985) Treatment of malignant pleural effusion. Chest 88:393-397
31. Luh KT, Yang PC, Kuo SH et al (1992) Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. Cancer 69:674-679
32. Yoshida K, Sugiura T, Takifuji N et al (2007) Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. Lung Cancer 58:362-368